Clinical Trials Fail

Imfinzi EV Bladder Cancer Breakthrough: AstraZeneca Reports Historic Survival Gains in VOLGA Study

By Clinical Trials & Data Desk
14 May 2026

The Phase III VOLGA trial has reached its primary endpoints, proving that the Imfinzi EV bladder cancer combination delivers historic survival gains in the perioperative setting.

Clinical Trials Healthcare & Pharmaceuticals Neuroscience News

Novo Nordisk’s Semaglutide Fails to Slow Alzheimer’s Progression in Phase 3 Trials; Shares Slide

By Clinical Trials & Data Desk
25 November 2025

Novo Nordisk announced today that its blockbuster drug semaglutide failed to slow the progression of early-stage Alzheimer’s disease in two large-scale Phase 3 clinical trials, [Read More…]

Tag: Clinical Trials Fail

Imfinzi EV Bladder Cancer Breakthrough: AstraZeneca Reports Historic Survival Gains in VOLGA Study

Novo Nordisk’s Semaglutide Fails to Slow Alzheimer’s Progression in Phase 3 Trials; Shares Slide

Areas Covered

Discover More

Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN

LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C

GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline

Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement